Literature DB >> 9049195

Autoimmune hepatitis in childhood: a 20-year experience.

G V Gregorio1, B Portmann, F Reid, P T Donaldson, D G Doherty, M McCartney, A P Mowat, D Vergani, G Mieli-Vergani.   

Abstract

To determine the clinical, biochemical, and histological features, and outcome of childhood autoimmune hepatitis (AIH), we reviewed the medical records of 52 children with AIH, 32 (median age: 10 [2-15] years) anti-nuclear and/or smooth muscle antibody (ANA/SMA) positive, 20 (7 [0.8-14] years) liver/kidney microsomal antibody (LKM-1) positive, with median follow-up of 5 years (range 0.3-19). At presentation: 56% had symptoms of prolonged acute hepatitis; LKM-1 positive were younger (P = .011), with higher bilirubin (P = .007), and AST (P = .047); ANA/SMA positive had lower albumin (P = .023); 69% ANA/SMA positive, and 38% LKM-1 positive were cirrhotic (P = .080). ANA/SMA positive had increased frequency of HLA haplotype A1/B8/DR3/DR52a compared with controls (53% vs. 14%, P < .001). Of six (5 LKM-1 positive) with fulminant hepatitis, four were transplanted, one died, and one ANA/SMA positive improved with immunosuppression. Of 47 treated with immunosuppression, 2 (1 LKM-1 positive) died with no remission and 4 (2 LKM-1 positive) were transplanted 8 to 14 years after diagnosis. Immunosuppression was stopped successfully in 19% of ANA/SMA positive after a median of 3 years of treatment, but in none of LKM-1 positive. Baseline bilirubin and international normalized prothrombin ratio (INR) were independent variables predictive of outcome. In conclusion, ANA/SMA positive and LKM-1 positive AIH in childhood have clinical, biochemical, and histological differences, but similar severity and long-term outcome.

Entities:  

Mesh:

Year:  1997        PMID: 9049195     DOI: 10.1002/hep.510250308

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  102 in total

Review 1.  Who needs a liver transplant? (new disease specific indications).

Authors:  A Baker; A Dhawan; N Heaton
Journal:  Arch Dis Child       Date:  1998-11       Impact factor: 3.791

Review 2.  Autoimmune hepatitis and its variant syndromes.

Authors:  Z Ben-Ari; A J Czaja
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

3.  Detection of liver kidney microsomal type 1 antibody using molecularly based immunoassays.

Authors:  N Kerkar; Y Ma; E T Davies; P Cheeseman; G Mieli-Vergani; D Vergani
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

Review 4.  Celiac disease in pediatric patients with autoimmune hepatitis: etiology, diagnosis, and management.

Authors:  Fabio Panetta; Valerio Nobili; Maria Rita Sartorelli; Raffaele Edo Papa; Francesca Ferretti; Arianna Alterio; Antonella Diamanti
Journal:  Paediatr Drugs       Date:  2012-02-01       Impact factor: 3.022

Review 5.  Genetic bases of autoimmune hepatitis.

Authors:  Albert J Czaja; Derek G Doherty; Peter T Donaldson
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

Review 6.  Autoantibodies as prognostic markers in autoimmune liver disease.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-05-13       Impact factor: 3.199

Review 7.  Targeting Hepatic Fibrosis in Autoimmune Hepatitis.

Authors:  Aldo J Montano-Loza; Ragesh B Thandassery; Albert J Czaja
Journal:  Dig Dis Sci       Date:  2016-07-19       Impact factor: 3.199

8.  Autoimmune hepatitis.

Authors:  Heike Bantel; Christian P Strassburg; Michael P Manns
Journal:  Curr Gastroenterol Rep       Date:  2005-05

9.  Is the new diagnostic scoring system of Zeniya and colleagues useful for autoimmune liver diseases?

Authors:  Norio Horiike; Morikazu Onji
Journal:  J Gastroenterol       Date:  2005-12       Impact factor: 7.527

Review 10.  Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2017-07-14       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.